Arctic Bioscience - Extension of share options to members of management group
Arctic Bioscience AS (ABS) · publisert 2024-03-15 09:22 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Yuming Feng Options agreement extended with Global Nutrios Consulting LLC, a legal person closely associated with Yuming Feng. nærstående | EVP Global Business Development | acquisition | – | 100 000 | 2024-03-15 | NO0010859580 | Outside a trading venue Appendix 3: Notification template for notifying transactions Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | rules · til gjennomgang |
| Daniele Mancinelli | CTO | acquisition | 51 570 | 9 845 | 2024-03-15 | NO0010859580 | Outside a trading venue Appendix 3: Notification template for notifying transactions Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | rules |
| Hogne Hallaråker | CSO | acquisition | 33 030 | 9 845 | 2024-03-15 | NO0010859580 | Outside a trading venue Appendix 3: Notification template for notifying transactions Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | rules |
| Per Christian Sæbø | COO | acquisition | 57 390 | 9 845 | 2024-03-15 | NO0010859580 | Outside a trading venue | rules |
Vedlegg
- 20240315_Appendix_3_Notifying_Transactions.pdf (tekst hentet ut)
Meldingstekst
The Board of Directors of Arctic Bioscience AS has resolved to extend the share
option agreements for the following members of the management group: Yuming Feng
(EVP Global Business Development), Daniele Mancinelli (CTO), Hogne Hallaråker
(CSO) and Per Christian Sæbø (COO).
The exercise prices in the agreement for Feng is maintained at NOK 27,90 per
share and maintained at NOK 9,845 per share in the agreements for Mancinelli,
Hallaråker and Sæbø. The duration of the option agreements is extended until 28.
February 2025.
All options being exercised into shares during the duration period will be
subject to a "lock-in" period of 12 months from the time of exercise, where the
shares cannot be sold or transferred without the consent of the Board.
After this, Yuming Feng holds 100 000 share options via Global Nutrios
Consulting LLC, Daniele Mancinelli holds 51 570 share options, Hogne Hallaråker
holds 33 030 share options and Per Christian Sæbø holds 57 390 share options.
Notifications of transactions by persons discharging managerial responsibilities
are attached hereto.
This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities
Trading Act § 5-12.
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.